Intelligence Platform
Patents
Browse 73 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 11667702
Stable aqueous formulations of aflibercept
granted patentUS 11583584
Stable protein compositions and methods of their use
granted patentUS 11576971
Method of filling a container with no headspace
granted patentUS 11426446
Stable aqueous formulations of aflibercept
granted patentUS 11400072
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
granted patentUS 11396540
Methods for making recombinant proteins
granted patentUS 11253508
PPARy agonist for treatment of progressive supranuclear palsy
granted patentUS 11229702
High concentration formulations of adalimumab
granted patentUS 11135267
Etanercept formulations stabilized with metal ions
granted patentUS 11129876
Etanercept formulations stabilized with amino acids
granted patentUS 11071782
Method of filling a container with no headspace
granted patentUS 11000588
Etanercept formulations stabilized with sodium chloride
granted patentUS 11001627
Correctly folded etanercept in high purity and excellent yield
granted patentUS 10987405
Method of reducing formation of etanercept aggregates or fragments
granted patentUS 10980885
Method of reducing formation of etanercept aggregates or fragments
granted patentUS 10980884
Stable aqueous etanercept composition
granted patentUS 10975138
Correctly folded etanercept composition
granted patentUS 10954295
Correctly folded etanercept in high purity and excellent yield
granted patentUS 10954294
Correctly folded etanercept in high purity and excellent yield
granted patentUS 10954293
Correctly folded etanercept in high purity and excellent yield
granted patentUS 10947306
Correctly folded etanercept in high purity and excellent yield
granted patentUS 10888619
Stable aqueous etanercept composition
granted patentUS 10822429
Etanercept formulations exhibiting marked reduction in sub-visible particles
granted patentUS 10799585
Stable aqueous formulations of adalimumab
granted